Itonis Pharmaceuticals Received Emesyl Samples for Evaluation
28 Februar 2014 - 7:49PM
Marketwired
Itonis Pharmaceuticals Received Emesyl Samples for Evaluation
LAGUNA HILLS, CA--(Marketwired - Feb 28, 2014) - Itonis, Inc.
(PINKSHEETS: ITNS) is pleased to announce that it has received and
is currently evaluating samples of its Emesyl™ product from its
manufacturer. Oasis Health Products, Inc. delivered two
versions of the Emesyl™ anti-nausea formula which are currently
being evaluating for tolerance.
"The two versions differ in terms of preservative," says Ernesto
Barron, Itonis' recently appointed Chief Scientific Officer. "We
are looking at using a class of preservative that will not only
maintain product stability but also will serve to sooth the nasal
passages."
About Itonis
Pharmaceuticals Itonis Pharmaceuticals, a new division of
Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's
mission is to create and market over-the-counter and prescription
homeopathic products that better people's lives. Dr. Hensley is a
pioneer in the development and marketing of safe and effective
therapeutic nutraceutical and homeopathic preparations. He was
a founder of the company that launched the Zicam® Cold Remedy,
making the product a household name and forever changing the
marketing and product placement paradigm for homeopathic drugs in
the United States. Dr. Hensley and his team plan to use the
same methodologies to revolutionize the treatment of several other
common ailments and other chronic diseases.
About Itonis,
Inc. Itonis, Inc. was incorporated in the state of Nevada on
July 5, 2005 under the name of Kenshou, Inc., which later changed
to Itonis, Inc. on December 2, 2005. Please visit
www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact: Itonis, Inc. Email Contact
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
Von Sep 2023 bis Sep 2024